A novel coronavirus from patients with pneumonia in China, N Engl J Med, vol.382, pp.727-760, 2019. ,
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges, Int J Antimicrob Agents, vol.2020, p.105924 ,
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, Int J Antimicrob Agents, 2020. ,
URL : https://hal.archives-ouvertes.fr/hal-02517890
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, vol.30, pp.269-71, 2020. ,
Chloroquine for the 2019 novel coronavirus SARS-CoV-2, Int J Antimicrob Agents, vol.2020, p.105923 ,
URL : https://hal.archives-ouvertes.fr/hal-02504553
Remdesivir for SARS-CoV-2 pneumonia, Int J Antimicrob Agents, 2020. ,
Teicoplanin potently blocks the cell entry of 2019-nCoV, 2020. ,
Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV), J Biol Chem, vol.291, pp.9218-9250, 2016. ,
Fighting viruses with antibiotics: an overlooked path, Int J Antimicrob Agents, vol.4, pp.34-43, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01455802
Use of teicoplanin anti-Middle East respiratory syndrome coronavirus. WIPO PatentScope, 2015. ,